The Senate Health, Education, Labor & Pensions Committee last night voted 13-9 to advance legislation that would reauthorize Food and Drug Administration user fee programs and modify the regulatory framework for laboratory developed tests. AHA last week urged lawmakers to consider certain changes to the LDT provisions to ensure continued access to these critical tests.  
 
The House last week passed its own bill (H.R. 7667) to reauthorize FDA user fee programs, which does not include the LDT provisions. Among other provisions, the House bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies. 
 

Related News Articles

Headline
The Department of Health and Human Services Office of Civil Rights yesterday announced a proposed rule with changes to the process for handling conscience…
Headline
President Biden late Thursday signed into law the $1.7 trillion omnibus bill that will keep the government funded through September 2023. H.R. 2617, the “…
Headline
The House and Senate  Appropriations Committees last night released the fiscal year 2023 Omnibus Appropriations legislation that would fund the government…
Headline
President Biden today signed a continuing resolution extending current federal funding levels for health care and other programs through Dec. 23. Passed by the…
Perspective
Challenges. Resilience. Innovation. Opportunities. These four words help describe the current environment facing our hospitals and health systems — nearly…
Headline
The Senate Finance Committee last week released draft legislation to improve mental health parity and access to behavioral health services in Medicare and…